Total Payments
$732,730
2024 Payments
$84,858
Companies
70
Transactions
1,939
Medicare Patients
2,385
Medicare Billing
$336,584
Payment Breakdown by Category
Other$525,465 (71.7%)
Consulting$92,133 (12.6%)
Travel$63,128 (8.6%)
Food & Beverage$36,666 (5.0%)
Research$14,525 (2.0%)
Education$813.63 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $513,180 | 197 | 70.0% |
| Consulting Fee | $92,133 | 48 | 12.6% |
| Travel and Lodging | $63,128 | 133 | 8.6% |
| Food and Beverage | $36,666 | 1,526 | 5.0% |
| Unspecified | $14,525 | 12 | 2.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $12,285 | 8 | 1.7% |
| Education | $813.63 | 15 | 0.1% |
Payments by Type
General
$718,205
1,927 transactions
Research
$14,525
6 transactions
Ownership
$0
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $232,329 | 300 | $0 (2024) |
| EMD Serono, Inc. | $205,879 | 267 | $0 (2024) |
| GENZYME CORPORATION | $104,366 | 133 | $0 (2024) |
| ACADIA Pharmaceuticals Inc | $64,719 | 90 | $0 (2024) |
| Avanir Pharmaceuticals, Inc. | $55,759 | 87 | $0 (2021) |
| Eisai Inc. | $23,384 | 36 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $16,712 | 106 | $0 (2024) |
| Lilly USA, LLC | $8,519 | 70 | $0 (2024) |
| Genentech USA, Inc. | $5,476 | 48 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $2,592 | 106 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $84,858 | 200 | EMD Serono, Inc. ($45,373) |
| 2023 | $55,792 | 184 | EMD Serono, Inc. ($32,695) |
| 2022 | $81,435 | 238 | EMD Serono, Inc. ($37,052) |
| 2021 | $133,053 | 285 | Biogen, Inc. ($83,971) |
| 2020 | $61,883 | 189 | Biogen, Inc. ($26,523) |
| 2019 | $88,192 | 236 | Biogen, Inc. ($26,547) |
| 2018 | $116,492 | 307 | Avanir Pharmaceuticals, Inc. ($27,327) |
| 2017 | $111,025 | 300 | Biogen, Inc. ($32,370) |
All Payment Transactions
1,939 individual payment records from CMS Open Payments — Page 1 of 78
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Grifols USA, LLC | Gamunex-C (Biological) | Food and Beverage | In-kind items and services | $18.68 | General |
| Category: Immunology and Neurology | ||||||
| 12/03/2024 | MDD US Operations, LLC | Gocovri (Drug) | Food and Beverage | In-kind items and services | $14.63 | General |
| Category: AMANTADINE | ||||||
| 12/03/2024 | Lilly USA, LLC | EMGALITY (Drug) | Food and Beverage | In-kind items and services | $10.34 | General |
| Category: Neuroscience | ||||||
| 11/27/2024 | PFIZER INC. | PANZYGA (Biological) | Food and Beverage | In-kind items and services | $13.84 | General |
| Category: IMMUNOLOGY;INFLAMMATION | ||||||
| 11/20/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $33.13 | General |
| Category: Neurology | ||||||
| 11/19/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,273.00 | General |
| Category: Neurology | ||||||
| 11/18/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $19.80 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 11/15/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $62.40 | General |
| 11/12/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $27.46 | General |
| 11/10/2024 | Biogen, Inc. | VUMERITY (Drug) | Food and Beverage | In-kind items and services | $18.54 | General |
| Category: Neurology | ||||||
| 11/08/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $17.34 | General |
| Category: Neurology | ||||||
| 11/07/2024 | Lilly USA, LLC | EMGALITY (Drug) | Food and Beverage | In-kind items and services | $12.26 | General |
| Category: Neuroscience | ||||||
| 11/03/2024 | MDD US Operations, LLC | Gocovri (Drug) | Food and Beverage | In-kind items and services | $19.30 | General |
| Category: AMANTADINE | ||||||
| 11/03/2024 | MDD US Operations, LLC | Gocovri (Drug) | Food and Beverage | In-kind items and services | $5.04 | General |
| Category: AMANTADINE | ||||||
| 10/31/2024 | ABBVIE INC. | QULIPTA (Drug), BOTOX | Food and Beverage | In-kind items and services | $17.29 | General |
| Category: NEUROSCIENCE | ||||||
| 10/30/2024 | Axsome Therapeutics, Inc. | Sunosi (Drug) | Food and Beverage | In-kind items and services | $17.15 | General |
| Category: Neurology | ||||||
| 10/30/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $9.91 | General |
| 10/29/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $29.40 | General |
| Category: Neurology | ||||||
| 10/28/2024 | Lilly USA, LLC | KISUNLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,100.00 | General |
| Category: Neuroscience | ||||||
| 10/28/2024 | Lilly USA, LLC | KISUNLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $800.00 | General |
| Category: Neuroscience | ||||||
| 10/24/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | Cash or cash equivalent | $103.77 | General |
| Category: Neuroscience | ||||||
| 10/24/2024 | Kyowa Kirin, Inc. | Nourianz (Drug) | Food and Beverage | In-kind items and services | $13.38 | General |
| Category: Adenosine A2A Receptors | ||||||
| 10/23/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $23.01 | General |
| Category: Neuropsychiatry | ||||||
| 10/23/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $11.32 | General |
| Category: Neurology | ||||||
| 10/22/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $1.72 | General |
| Category: Neuropsychiatry | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ACA 16-cAC-0001 | ACADIA Pharmaceuticals Inc | $14,525 | 6 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 493 | 553 | $185,156 | $68,374 |
| 2022 | 11 | 565 | 695 | $223,239 | $78,831 |
| 2021 | 10 | 653 | 776 | $269,235 | $95,957 |
| 2020 | 12 | 674 | 752 | $265,274 | $93,423 |
Total Patients
2,385
Total Services
2,776
Medicare Billing
$336,584
Procedure Codes
46
All Medicare Procedures & Services
46 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 103 | 103 | $36,977 | $15,833 | 42.8% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2023 | 42 | 42 | $27,300 | $11,369 | 41.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 79 | 89 | $21,271 | $10,242 | 48.2% |
| 95957 | Measurement of brain wave activity (eeg), digital analysis | Office | 2023 | 42 | 42 | $32,928 | $8,781 | 26.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 77 | 86 | $15,409 | $6,808 | 44.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 32 | 34 | $17,952 | $4,646 | 25.9% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 31 | 62 | $14,572 | $4,292 | 29.5% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2023 | 18 | 18 | $6,750 | $1,997 | 29.6% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2023 | 13 | 13 | $5,661 | $1,726 | 30.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 14 | 16 | $2,928 | $1,500 | 51.2% |
| 96138 | Administration of psychological or neuropsychological test by technician, first 30 minutes | Office | 2023 | 42 | 48 | $3,408 | $1,180 | 34.6% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 103 | 205 | $48,883 | $14,833 | 30.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 91 | 91 | $32,669 | $13,132 | 40.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 83 | 100 | $24,018 | $12,001 | 50.0% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2022 | 31 | 31 | $20,150 | $8,369 | 41.5% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2022 | 65 | 65 | $24,168 | $7,732 | 32.0% |
| 95957 | Measurement of brain wave activity (eeg), digital analysis | Office | 2022 | 31 | 31 | $24,304 | $6,135 | 25.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 62 | 68 | $12,365 | $5,676 | 45.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 35 | 35 | $17,570 | $5,086 | 28.9% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2022 | 32 | 32 | $14,528 | $3,926 | 27.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 15 | 19 | $3,306 | $1,480 | 44.8% |
| 96138 | Administration of psychological or neuropsychological test by technician, first 30 minutes | Office | 2022 | 17 | 18 | $1,278 | $460.00 | 36.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 97 | 97 | $34,975 | $14,707 | 42.1% |
| 95816 | Measurement and recording of brain wave (eeg) activity, awake and drowsy | Office | 2021 | 56 | 56 | $36,400 | $14,452 | 39.7% |
| 95886 | Needle measurement and recording of electrical activity of muscles of arm or leg complete study | Office | 2021 | 98 | 195 | $46,166 | $14,187 | 30.7% |
About Dr. Kenneth Pugar, D.O
Dr. Kenneth Pugar, D.O is a Neurology healthcare provider based in Centerville, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/11/2005. The National Provider Identifier (NPI) number assigned to this provider is 1528060399.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kenneth Pugar, D.O has received a total of $732,730 in payments from pharmaceutical and medical device companies, with $84,858 received in 2024. These payments were reported across 1,939 transactions from 70 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($513,180).
As a Medicare-enrolled provider, Pugar has provided services to 2,385 Medicare beneficiaries, totaling 2,776 services with total Medicare billing of $336,584. Data is available for 4 years (2020–2023), covering 46 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Centerville, OH
- Active Since 08/11/2005
- Last Updated 07/03/2024
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1528060399
Products in Payments
- Mavenclad (Drug) $112,687
- TYSABRI (Biological) $85,829
- NUPLAZID (Drug) $64,719
- NUEDEXTA (Drug) $55,757
- Rebif (Biological) $41,869
- DISEASE STATE (Drug) $34,012
- MAVENCLAD (Drug) $32,007
- AUBAGIO (Drug) $24,324
- TECFIDERA (Drug) $23,670
- Leqembi (Drug) $23,270
- VUMERITY (Drug) $15,502
- COPAXONE (Drug) $15,422
- Mavenclad (Biological) $13,204
- Tysabri (Biological) $9,675
- KISUNLA (Drug) $5,650
- OCREVUS (Biological) $5,483
- ADUHELM (Biological) $4,685
- Rebif (Drug) $2,150
- AMYVID (Drug) $1,273
- NURTEC ODT (Drug) $1,069
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Centerville
Dr. Timothy Schoonover, D.o, D.O
Neurology — Payments: $432,352
Neurology $432,352
Dr. Jon Durrani, Do, DO
Neurology — Payments: $278,951
Neurology $278,951
Megan Mackenzie, D.o, D.O
Neurology — Payments: $66,466
Neurology $66,466
Mrs. Sarah Dooley, P.a, P.A
Neurology — Payments: $12,580
Neurology $12,580
Dr. Nicole Alexander, D.o, D.O
Neurology — Payments: $11,068
Neurology $11,068
Dr. Petre Udrea, M.d, M.D
Neurology — Payments: $5,481
Neurology $5,481